Document:

EX-10.4

 Exhibit 10.4 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

US Education Collaboration Agreement 

This Agreement is entered into with effect as of the Effective Date (as defined below) 

by and between 
 Genentech, Inc. 

with an office and place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) 

and 
 Foundation Medicine, Inc. 

with an office and place of business at 150 Second Street, Cambridge, Massachusetts 02141 (“FMI”) on the other hand. 

  

 Table of Contents 

 

									
	1.		Definitions		 	5	  
			1.1		Affiliate		 	5	  
			1.2		Agreement		 	5	  
			1.3		Agreement Term		 	5	  
			1.4		Applicable Law		 	5	  
			1.5		Business Day		 	5	  
			1.6		Calendar Quarter		 	5	  
			1.7		Calendar Year		 	5	  
			1.8		CGP		 	5	  
			1.9		Commercially Reasonable Efforts		 	5	  
			1.10		Confidential Information		 	6	  
			1.11		Control		 	6	  
			1.12		Educational Materials		 	6	  
			1.13		Education Support Program		 	6	  
			1.14		Education Support Working Group		 	6	  
			1.15		Effective Date		 	6	  
			1.16		FDCA		 	6	  
			1.17		FTE		 	6	  
			1.18		FTE Rate		 	6	  
			1.19		Government Agency		 	7	  
			1.20		Healthcare Laws		 	7	  
			1.21		Insolvency Event		 	7	  
			1.22		JOC		 	7	  
			1.23		Know-How		 	7	  
			1.24		Party		 	7	  
			1.25		PREP Team		 	7	  
			1.26		Regulatory Authority		 	7	  
			1.27		Roche Group		 	7	  
			1.28		Tactical Plan		 	8	  
			1.29		Third Party		 	8	  
			1.30		US		 	8	  
			1.31		US$		 	8	  
			1.32		Additional Definitions		 	8	  
	2.		US Education Collaboration		 	9	  
			2.1		Education Support Program		 	9	  
			2.2		Governance		 	13	  
	3.		Costs		 	15	  
			3.1		[...***...]		 	15	  
			3.2		Other Costs		 	15	  
			3.3		Disclosure of Payments		 	15	  
	4.		Payments		 	15	  
			4.1		Timing of Payments		 	15	  
			4.2		Late Payments		 	15	  
			4.3		Method of Payments		 	15	  

  
 - 2 - 

									
	5.		Co-Promote Option		 	16	  
	6.		Intellectual Property		 	16	  
			6.1		Ownership and Use		 	16	  
			6.2		No Implied Licenses		 	17	  
	7.		Representations and Warranties		 	17	  
			7.1		Mutual Representations and Warranties		 	17	  
			7.2		No Other Representations		 	18	  
	8.		Liability		 	18	  
	9.		Term and Termination		 	18	  
			9.1		Commencement and Term		 	18	  
			9.2		Termination		 	18	  
			9.3		Consequences of Termination		 	19	  
			9.4		Survival		 	19	  
	10.		Matters Governed by the Collaboration Agreement		 	20	  
			10.1		Auditing		 	20	  
			10.2		Indemnification		 	20	  
			10.3		Confidentiality		 	20	  
			10.4		Assignment		 	20	  
			10.5		Debarment and Exclusion		 	20	  
	11.		Miscellaneous		 	20	  
			11.1		Governing Law		 	20	  
			11.2		Disputes		 	20	  
			11.3		Independent Contractor		 	21	  
			11.4		Unenforceable Provisions and Severability		 	21	  
			11.5		Waiver		 	21	  
			11.6		Appendices		 	21	  
			11.7		Entire Understanding		 	21	  
			11.8		Amendments		 	21	  
			11.9		Invoices		 	21	  
			11.10		Notice		 	22	  

  
 - 3 - 

 US Education Collaboration Agreement 

WHEREAS, FMI has or is developing platforms for use in genomic testing, and has expertise in comprehensive genomic profiling and next generation sequencing
technology; and 
 WHEREAS, Genentech has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic
products; and 
 WHEREAS, Genentech wishes to extend its leadership position in education in personalized healthcare and genetic testing by adding
comprehensive genomic profiling to its educational offerings for pathologists and laboratories; and 
 WHEREAS, Genentech is able to undertake such
educational efforts at this time based, in part, on the financial contribution that FMI is providing hereunder; and 
 WHEREAS, Genentech and FMI want to
work together in the United States to educate relevant persons on comprehensive genomic profiling technology; and 
 WHEREAS, FMI and
Genentech’s Affiliates F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”; Roche Basel and Roche US together referred to as
“Roche”) are engaged in a series of transactions, including (a) agreements under which Roche will acquire a majority ownership of FMI, (b) an agreement under which Roche will be responsible for the commercialization of
certain FMI diagnostic products outside of the United States (“Ex-US Commercialization Agreement”), (c) a term sheet under which FMI and Roche will potentially collaborate on the
development of in vitro diagnostic kits, and (d) an agreement under which FMI and Roche will collaborate on the development of platforms for use in molecular information, immunotherapy, circulating tumor DNA, and
companion diagnostics (“Collaboration Agreement”), the foregoing agreements and term sheet referred to collectively as the “Related Agreements”; and  

WHEREAS, FMI and Genentech intend that the governance structure under the Collaboration Agreement will apply to certain matters under this Agreement. 

  
 - 4 - 

 NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	1.1	Affiliate 

 The term “Affiliate” shall have the meaning set forth in the Collaboration
Agreement, provided that references to Roche shall be replaced by references to Genentech. 
  

	1.2	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	1.3	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and expiring five (5) years thereafter, unless such period is extended by the written agreement of the Parties. 
  

	1.4	Applicable Law 

 The term “Applicable Law” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.5	Business Day 

 The term “Business Day” shall mean 9:00 am to 5:00 pm local time on a
day other than a Saturday, Sunday or bank or other public or federal holiday in California or Massachusetts. 
  

	1.6	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30 and December 31. 
  

	1.7	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first Calendar Year, which shall begin on the Effective Date and end on December 31. 
  

	1.8	CGP 

 The term “CGP” shall mean comprehensive genomic profiling, which may include using next
generation sequencing technology. 
  

	1.9	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean efforts
and resources comparable with the efforts and resources Genentech or FMI, as applicable, devotes to a similar obligation in connection with projects of a similar nature. 

  
 - 5 - 

	1.10	Confidential Information 

 The term “Confidential Information” shall have the meaning set forth
in the Collaboration Agreement. The terms of this Agreement shall be considered Confidential Information of the Parties. 
  

	1.11	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls,” “Controlled” or “Controlling”) (a) with respect to Know-How and intellectual property rights, the possession by a Party of the ability to grant a license or sublicense of such
Know-How and intellectual property rights without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such
proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 
  

	1.12	Educational Materials 

 The term “Educational Materials” shall mean materials intended to
educate healthcare professionals about CGP, which Genentech shall develop for its own use. 
  

	1.13	Education Support Program 

 The term “Education Support Program” shall mean a program under
which (a) FMI shall train PREP Team members about CGP; (b) Genentech shall develop the Educational Materials; and (c) PREP Team members, and other representatives of Genentech, shall conduct Educational Activities and
perform other activities related to CGP education directed to healthcare professionals. 
  

	1.14	Education Support Working Group 

 The term “Education Support Working Group” or
“ESWG” shall mean the group of persons from both Parties who will handle the day-to-day activities associated with the Education Support Program. 
  

	1.15	Effective Date 

 The term “Effective Date” shall mean the date on which the Collaboration
Agreement becomes effective. 
  

	1.16	FDCA 

 The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 

 

	1.17	FTE 

 The term “FTE” shall mean a full-time equivalent
person-year, based upon a total of no less than one thousand eight hundred (1,800) working hours per year. In no circumstance can the work of any given person exceed one (1) FTE. 

 

	1.18	FTE Rate 

 The term “FTE Rate” shall mean [...***...] per FTE on a fully burdened
cost basis, which amount shall be subject to increase using the methodology for increasing the FTE Rate under the Collaboration Agreement mutatis mutandis. 

  
 ***Confidential Treatment
Requested*** 
 - 6 - 

	1.19	Government Agency 

 The term “Government Agency” shall mean any department or agency of the US
or any US state government with the authority to interpret, regulate under or enforce any Healthcare Laws, which may include a US or US state Regulatory Authority. 
  

	1.20	Healthcare Laws 

 The term “Healthcare Laws” shall mean (a) criminal and civil federal and
state fraud and laws including, without limitation, the Civil False Claims Act (31 USC §§ 3729-3733), the Criminal False Claims Act (18 USC § 287), the Anti-Kickback Statute (42 USC § 1320A-7b(b)) and associated regulatory safe harbors (42 CFR § 1001.952), the Physician Self-Referral Law
(42 USC § 1395nn), the Criminal Health Care Fraud (18 USC § 1347), the Exclusion Statute (42 USC Section 1320a-7) and the Civil Monetary Penalties Law (42 USC § 1320a-7a); and any US state law equivalents of any of the foregoing; (b) criminal and civil federal and state drug and medical device marketing, advertising and promotional laws, including without
limitation the FDCA, and any US state law equivalents thereof; and (c) criminal and civil federal and state consumer protection laws including without limitation Federal Trade Commission Act (15 U.S.C. §§ 41-58); and any US state law
equivalents thereof. 
  

	1.21	Insolvency Event 

 The term “Insolvency Event” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.22	JOC 

 The term “JOC” shall mean the joint operating committee described in the Ex-US Commercialization Agreement. 
  

	1.23	Know-How 

 The term “Know-How” shall mean data,
knowledge and information, including related to CGP, manufacturing data, toxicological data, pharmacological data, preclinical data, formulations, specifications, quality control testing data. 

 

	1.24	Party 

 The term “Party” shall mean FMI or Genentech, as the case may be, and
“Parties” shall mean FMI and Genentech collectively. 
  

	1.25	PREP Team 

 The term “PREP Team” shall mean Genentech’s field-based team of professions referred to as the PREP (Program for Reaching and Educating about Pathology) team, or any other Genentech group performing similar functions, as further described in the Tactical
Plan. 
  

	1.26	Regulatory Authority 

 The term “Regulatory Authority” shall have the meaning set forth in the
Collaboration Agreement. 
  

	1.27	Roche Group 

 The term “Roche Group” shall have the meaning set forth in the Collaboration
Agreement. 

  
 - 7 - 

	1.28	Tactical Plan 

 The term “Tactical Plan” shall mean a plan for the [...***...] that
describes the responsibilities of the Parties for implementing the Education Support Program, as further described in Section 2.1.5. 
  

	1.29	Third Party 

 The term “Third Party” shall mean a person or entity other than (a) FMI or
any of its Affiliates or (b) a member of the Roche Group. 
  

	1.30	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	1.31	US$ 

 The term “US$” shall mean US dollars. 

 

	1.32	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	Bankruptcy Code	  	9.3.2
	Breaching Party	  	9.2.1
	Collaboration Agreement	  	Whereas Clause
	Educational Activities	  	2.1.1
	ESWG	  	1.14
	ESWG Co-Leader	  	2.2.1
	Ex-US Collaboration Agreement	  	Whereas Clause
	FMI Other Materials	  	6.1.3
	FMI Provided Materials	  	6.1.1
	FTE Costs	  	3.1
	Non-Breaching Party	  	9.2.1
	Other Costs	  	3.1
	Payment Currency	  	4.3
	Peremptory Notice Period	  	9.2.1
	Related Agreements	  	Whereas Clause
	Roche	  	Whereas Clause
	Roche Basel	  	Whereas Clause
	Roche US	  	Whereas Clause
	[...***...]	  	3.1
	Training Activities	  	2.1.2
	Training Materials	  	2.1.2

  
 ***Confidential Treatment
Requested*** 
 - 8 - 

	2.	US Education Collaboration 

  

	2.1	Education Support Program 

  

	 	2.1.1	Scope 

 Genentech and FMI shall conduct the Education Support Program pursuant to a mutually agreed Tactical
Plan under the direction of the Education Support Working Group (also referred to as the “ESWG”). The purpose of the Education Support Program is for Genentech to provide education support directed to healthcare professionals regarding
comprehensive genomic profiling (CGP), using next generation sequencing technology or other technologies that may emerge for CGP (“Educational Activities”). 
  

	 	2.1.2	Training Activities and Training Materials 

 FMI shall provide training to Genentech regarding CGP and other
topics, as agreed to by the Parties in the Tactical Plan, subject to the limitations in Section 2.1.7 and other provisions of this Agreement (“Training Activities”). The Training Activities shall take place in the location and on
the schedule in the Tactical Plan. As part of the Training Activities, FMI shall provide to Genentech information and materials related to CGP (“Training Materials”). FMI shall prepare the Training Activities and Training Materials
with content based on competent and reliable scientific and medical principles. The Training Activities and Training Materials must be non-commercial in tone, focus and content and must make a fair and
balanced representation of the positive and negative attributes and uncertainties of CGP. The Training Activities and Training Materials must not incorporate promotional, commercial or marketing messages for FMI or its products including, without
limitation, FoundationOne or FoundationOne Heme. Notwithstanding anything to the contrary, in conducting the Training Activities, FMI may use its proprietary platform and CGP testing panels to provide a specific demonstration of how CGP may be
performed. 
  

	 	2.1.3	Educational Materials 

 FMI shall provide the Training Materials to Genentech in hardcopy form and in electronic
form for use in preparing the Educational Materials. Genentech shall be responsible, in collaboration with FMI, for developing the content and appearance of the Educational Materials, to be used by Genentech as part of the Education Support Program.
In preparing the Educational Materials, Genentech will draw upon relevant information included in the Training Activities, upon the relevant expertise of the PREP Team and other Genentech and Roche experts, and upon external sources of scientific
and medical information that Roche/Genentech determines to be competent and reliable. The Educational Materials will include only scientific and medical information regarding CGP that Genentech determines to be competent and reliable and will make a
fair and balanced presentation of the positive and negative attributes and uncertainties of CGP. Genentech shall provide a copy of the Educational Materials to FMI for review and comment; provided, however, Genentech shall have final decision making
authority regarding the Educational Materials. 

  
 - 9 - 

	 	2.1.4	Additional and Updated Training Activities 

 The Education Support Working Group shall confer regarding the
need, timing and location for (a) additional Training Activities for members who join the PREP Team after the initial Training Activities occur and (b) updated Training Activities for previously trained PREP Team members, based
on the emergence of new technology relevant to CGP. FMI and Genentech shall, respectively, use Commercially Reasonable Efforts to provide and attend any such additional or updated Training Activities. 

 

	 	2.1.5	Tactical Plan 

 The Tactical Plan in effect as of the Effective Date is attached as Appendix 2.1.5.
Genentech shall update the Tactical Plan [...***...], on the schedule determined by the Education Support Working Group (and at times as otherwise agreed by the ESWG, including for additional and updated Training Activities, as described in
Section 2.1.4), for review and approval by the ESWG. The details included in the Tactical Plan will vary to address the objectives of the Parties, but shall include, as applicable, details regarding (a) the Training Activities, including
training materials and timelines; (b) the scope of the Educational Materials and a plan for developing them; (c) the scope and target audiences for the Educational Activities by the PREP Team, using the Educational Materials or
otherwise; (d) a budget of estimated [...***...], and each Party’s portion of particular [...***...] (which portions may vary for particular costs); and (e) information to be shared by the Parties and the timing and means
for sharing such information (e.g., through the ESWG or otherwise). For any Educational Activities in a Tactical Plan conducted by PREP Team members, the Parties agree that any activities that Genentech agrees to perform will be reduced
pro rata for any period of time that a PREP team position is unstaffed and that an unstaffed position will not be deemed filled until a PREP Team member has attended Training Activities and been trained on the Educational Materials.
Information that one Party shares with or provides to the other Party under the Tactical Plan shall be Confidential Information of the sharing or providing Party. 
  

	 	2.1.6	Regulatory and Compliance Matters 

 (a) The Parties intend that (i) the Parties’
activities will be in all respects compliant with Applicable Laws and (ii) Genentech’s Educational Activities under the Tactical Plan will be structured and conducted so as to be educational disease awareness communications disseminated to
healthcare professionals that discuss a particular disease or health condition, in order to encourage awareness of signs of the particular disease or heath condition or otherwise provide information to assist in the diagnosis of the particular
disease or health condition, but do not mention any specific drug or device or make any representation or suggestion concerning a particular drug or device, and do not otherwise constitute product advertising or promotional labeling of a drug or
medical device. 
 (b) Each Party shall be solely responsible for matters of compliance with Applicable Laws with respect to its conduct of
activities under this Agreement and for interactions with Regulatory Authorities and Government Agencies with respect thereto, as follows: FMI shall be responsible for 

  
 ***Confidential Treatment
Requested*** 
 - 10 - 

 
its conduct of the Training Activities; Genentech shall be responsible for its preparation of the Educational Materials and the conduct of the Educational Activities; and both Parties will be
responsible for the establishment of priorities and tactics in the Tactical Plan and for discussions and sharing of information at the Education Support Working Group and otherwise between the Parties under this Agreement. If either Party receives a
communication from a Regulatory Authority or Government Agency that its activities under this Agreement may violate or have violated any Applicable Law or regulation, including any notice of claim, demand, suit, investigation or proceeding that
relates or may reasonably relate to any such activities, such Party shall promptly share that communication with the other Party, and the Parties shall confer on an appropriate response, provided that (i) the Party receiving the communication
shall remain free to take any or no action in response to such communication including, without limitation, terminating this Agreement under Section 9.2.2 and (ii) if both Parties are responsible for any of the activities under this Agreement
(as specified in this Section 2.1.6(b)) potentially relevant to such claim, demand, suit, investigation or proceeding, then the Parties shall discuss in good faith how to respond to it and how to handle it in an efficient manner. 

 

	 	2.1.7	Limitations on Activities 

 The Parties acknowledge and agree to the following: 

(a) This Agreement (individually or together with the Related Agreements) is not intended for the promotion in the US by Genentech of any
Genentech products or any FMI products or services (including, without limitation, FoundationOne or FoundationOne Heme) or for the promotion in the US by FMI of any Genentech products or any FMI products or services (including, without limitation,
FoundationOne or FoundationOne Heme), provided that nothing in the foregoing or elsewhere in this Agreement or the Related Agreements shall limit each Party in promoting its own products or services separate from and outside the scope of this
Agreement and the Related Agreements. 
 (b) Neither Party shall, under this Agreement, provide to or discuss with the other Party any of
such Party’s promotional strategies, plans or tactics for its products or services. Notwithstanding the foregoing, the Parties may discuss any activities of the PREP Team. 

(c) Genentech and its agents shall not recommend or mention FMI products or services (including, without limitation, FoundationOne or
FoundationOne Heme) in the course of Educational Activities and will not refer any audiences to FMI or its products or services. The Educational Materials and educational messaging that Genentech uses in the Educational Activities shall not include
any branding or references to either Party’s products or services. Notwithstanding the foregoing, company level branding (e.g., a Party’s logo) may be included as required by Applicable Law or accepted industry codes or practices, or
for purposes of corporate transparency. Without limiting the foregoing, any such branding shall be subject to the agreement of the Parties through the Education Support Working Group. Without limiting the generality of the foregoing, any promotion,
recommendation, or referral by either Party of or to the other or the other’s products or services in the US may only occur pursuant to a separate agreement or an amendment to this Agreement. 

(d) The Parties acknowledge that, currently, reports for patients generated through FoundationOne include mention of Genentech products as
being approved to treat tumors with 

  
 - 11 - 

 
particular types of mutations identified in such patients’ tumors in the FoundationOne test and the same may be done in the future for the FoundationOne Heme test on the same principles. The
Parties do not intend, through this Agreement or any Related Agreement, to compensate, encourage or incentivize FMI to make, change or prioritize such mentions of Genentech products in FoundationOne or as part of any other FMI product or services.
FMI covenants that it will not, by reason of its relationships with Genentech or Roche under this Agreement or the Related Agreements, change its practices in how it promotes, advertises, offers or provides FoundationOne, FoundationOne Heme or any
other product or service that it offers (including, without limitation, by changing how Genentech products are presented or mentioned in any such product or service report or how any potential association between a reported mutation and a Genentech
product is presented or mentioned). 
  

	 	2.1.8	Diligence and Activities 

 The Parties shall use Commercially Reasonable Efforts to perform their respective
activities under the Tactical Plan and as otherwise contemplated by this Agreement. The Parties shall perform all activities under this Agreement (a) in a professional manner; (b) in conformance with the level or care and skill ordinarily
exercised by other professional institutions in similar circumstances; and (c) in compliance with Applicable Law. 
  

	 	2.1.9	Third Party Contractors and Affiliates 

 Neither Party shall have the right to subcontract to Third Parties the
work for which it is responsible under the Tactical Plan or otherwise under this Agreement, except for activities customarily subcontracted by such Party, including the preparation or production of Training Materials or Educational Materials
and planning or coordination of Training Activities or Educational Activities. For clarity, none of the following activities may be subcontracted without the other Party’s prior written consent to subcontract (which may be provided by email to
the subcontracting Party’s ESWG Co-Leader): (a) for Genentech, (i) membership on, and participation in discussions and decision making of, the ESWG; (ii) PREP Team attendance at Training
Activities; (iii) oversight of preparation of, and final review and approval of, Educational Materials; (iv) educational calls including CGP education that are made by PREP Team members on healthcare professionals, laboratories and others
included within the target audience, as described in the Tactical Plan; (v) oversight of preparation of, and final review and approval of, materials for unbranded speaker programs including CGP education, as described in the Tactical Plan and
included in Educational Activities; (vi) on-site presence for and oversight of unbranded speaker programs including CGP education, as described in the Tactical Plan and included in Educational Activities; (vii) information-sharing as
required under the Tactical Plan; and (viii) discussions with FMI on communications from Government Agencies under Section 2.1.6(b) and (b) for FMI, (i) membership on, and participation in discussions and decision making of, the ESWG;
(ii) oversight of preparation of, and final review and approval of, Training Materials; (iii) conduct of Training Activities; (iv) information-sharing as required under the Tactical Plan; and (v) discussions with Genentech on
communications from Government Agencies under Section 2.1.6(b). Each Party shall have the right to perform its obligations under this Agreement through its Affiliates. Each Party shall remain fully responsible for and liable to the other Party
for the performance of activities under this Agreement by such Third Parties or Affiliates. 

  
 - 12 - 

	2.2	Governance 

  

	 	2.2.1	Establishment of the ESWG 

 The Parties shall establish the Education Support Working Group within
[...***...] after the Effective Date to operationalize the Education Support Program. The ESWG shall be composed of at least two (2), but no more than three (3) representatives designated by each Party (and the Parties need not have the
same number of representatives). The representatives shall be appropriate (in terms of their seniority, availability, function in their respective organizations, training and experience) for the activities for which the ESWG is responsible. Each
Party shall designate one of its representatives as its primary contact for ESWG matters (such Party’s “ESWG Co-Leader”). A Party may replace any or all of its representatives (and
designated ESWG Co-Leader) at any time by informing the other Party’s ESWG Co-Leader in advance, in writing (which may be by email). 

 

	 	2.2.2	Responsibilities of the ESWG 

 The Education Support Working Group shall: 

(a) review and approve [...***...] Tactical Plans and revisions to the Tactical Plans, each of which [...***...] plan and revision
Genentech shall prepare in accordance with Section 2.1.5; 
 (b) serve as a forum for coordinating the Parties’ efforts to carry
out the Tactical Plan; 
 (c) monitor the progress of activities under the Tactical Plan and discuss any obstacles or delays with regard to
achieving the timelines set forth therein; 
 (d) within [...***...] following the end of each [...***...] in which
[...***...] are incurred by a Party, coordinate, and/or be the primary conduit for, providing to the other Party a good faith estimate of such incurred [...***...] (which may differ from the actual invoice) in writing (which may be by
email); 
 (e) provide reports and other information to the JOC regarding activities under the Tactical Plan, as requested by the JOC; 

(f) coordinate, and/or be the primary conduit for, the transfer of information between the Parties, as required by the Tactical Plan; and 

(g) perform other responsibilities as may be assigned to the ESWG in or pursuant to this Agreement or as may be otherwise agreed by the
Parties in writing. 
  

	 	2.2.3	Decision Making Authority of the ESWG 

 With respect to the responsibilities of the Education Support Working
Group, each Party shall have one (1) collective vote in all decisions, and the Parties shall attempt to make decisions by reaching agreement. Except with respect to matters for which one Party expressly has final decision making authority
(e.g., Section 2.1.2 with respect to Educational Materials), if the ESWG cannot reach agreement within [...***...]. Genentech acknowledges that it will be represented by Roche on the JOC. The ESWG has no authority to amend, or to
waive compliance with, any provisions of this Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 13 - 

	 	2.2.4	ESWG Co-Leaders 

 Genentech’s ESWG Co-Leader (or its designee)
shall be responsible for the following: (a) scheduling Education Support Working Group meetings and setting meeting agendas; (b) calling emergency ESWG meetings; and (c) any additional responsibilities specified in the Agreement;
provided, however, FMI’s Co-Leader has the right to schedule meetings, raise matters for discussion and put matters to a vote. 
  

	 	2.2.5	Meetings; Attendees 

 Once established, the Education Support Working Group shall meet at least once each
[...***...] (unless otherwise agreed by the Parties), and shall meet at such other times as deemed appropriate by the ESWG. The ESWG may meet in person or via teleconference, video conference or the like, provided that at least
[...***...] shall be held in person, unless otherwise agreed by the Parties. Each Party shall bear the expense of its respective representatives’ participation in ESWG meetings. If a Party’s representative (including its ESWG Co-Leader) is unable to attend a given meeting, such Party may designate a knowledgeable alternate to attend such meeting and perform the functions of such representative. Each Party may, subject to providing prior
notice to the other Party’s ESWG Co-Leader (which may be by email), invite a reasonable number of non-voting employees, consultants or advisors to attend ESWG
meetings, provided that such invitees are bound by confidentiality and non-use obligations reasonably similar to the Parties’ obligations under this Agreement. In addition to formal meetings, the ESWG
representatives shall communicate as necessary to ensure the appropriate direction of the Education Support Program. 
  

	 	2.2.6	Minutes; Other Documentation of Decisions 

 Promptly after the Education Support Working Group is established,
it shall hold an organizational meeting to define the ESWG’s operating procedures, including for establishing agendas and preparing and approving minutes. Genentech shall be responsible for keeping minutes of ESWG meetings that record in
writing all decisions made, action items assigned or completed and other appropriate matters. Meeting minutes shall be sent to both Parties promptly after a meeting for review, comment and approval by each Party. A decision that may be made at a
ESWG meeting may also be made, without a meeting, if such decision is agreed to in writing (including by email) by each Party’s ESWG Co-Leader (or its designee), provided that each Party’s writing
clearly indicates that such decision is a formal decision by such Party’s ESWG Co-Leader. Any modifications to the Tactical Plan approved at a ESWG meeting (in accordance with the decision making
authority provisions of Section 2.2.3) shall constitute an amendment to such Tactical Plan upon approval by both Parties of the meeting minutes related thereto. 
  

	 	2.2.7	Term of ESWG Operations 

 The Education Support Working Group shall exist during the Agreement Term. 

  
 ***Confidential Treatment
Requested*** 
 - 14 - 

	3.	Costs 

  

	3.1	[...***...] 

 In accordance with the Tactical Plan, the Parties shall share [...***...]. FMI shall
reimburse Genentech for [...***...]. 
  

	3.2	Other Costs 

 Unless otherwise expressly agreed in the Tactical Plan, each Party shall bear the costs it
incurs in connection with the Training Activities and/or Educational Activities, including transportation, meals, lodging and the time necessary for representatives to prepare for and attend the Training Activities. Genentech shall be solely
responsible for the costs of producing the Educational Materials. 
  

	3.3	Disclosure of Payments 

 Each Party acknowledges that the other Party may be obligated to disclose
financial arrangements made with third parties to carry out certain activities under the Tactical Plan, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act.

  

	4.	Payments 

  

	4.1	Timing of Payments 

 FMI shall pay its portion of the [...***...] in arrears. Each
[...***...], Genentech shall invoice FMI for its portion of actual [...***...] incurred in the previous [...***...]. Invoices shall be payable within [...***...] after receipt by FMI of an invoice from Genentech. 

 

	4.2	Late Payments 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by Applicable Law, at [...***...] above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is
overdue. 
  

	4.3	Method of Payments 

 All amounts payable hereunder shall be paid in US dollars (the “Payment
Currency”) to account(s) designated by Genentech. 

  
 ***Confidential Treatment
Requested*** 
 - 15 - 

	5.	Co-Promote Option 

 If FMI seeks to promote a CDx (as defined in the Collaboration Agreement) for a
Genentech therapeutic in the US, then FMI shall first notify Genentech in writing and offer to Genentech [...***...]. Genentech shall have [...***...] from the receipt of such notice from FMI to provide FMI with [...***...]. If at
the end of such [...***...] period Genentech has not provided FMI with written notice [...***...], then FMI shall have no further obligation with respect to [...***...]. If Genentech properly [...***...], then the Parties
shall [...***...]. Notwithstanding the foregoing, FMI shall have the right to promote such product alone, at any time during such [...***...], and following such [...***...] period, in combination with one or more Third Parties. In
addition to the provisions surviving under Section 9.4, this Section shall survive the expiration or termination of this Agreement for so long as the CDx Development Program (as defined in the Collaboration Agreement) remains in effect, except
in the case of termination by FMI for Genentech’s material breach. 
  

	6.	Intellectual Property 

  

	6.1	Ownership and Use 

  

	 	6.1.1	FMI Provided Materials 

 In connection with the Training Activities (or otherwise under this Agreement), FMI may
provide to Genentech certain Know-How and other materials (“FMI Provided Materials”). FMI shall only provide FMI Provided Materials to Genentech that FMI Controls and otherwise has all
necessary rights to (a) provide such FMI Provided Materials to Genentech and (b) grant the license under Section 6.1.2 to Genentech and its Affiliates. FMI possesses (or may possess) proprietary rights (e.g., copyrights) in
certain of the FMI Provided Materials and, as between the Parties (subject to such license to Genentech), FMI shall solely own all right, title and interest in and to the FMI Provided Materials. For the avoidance of doubt, certain FMI
Provided Materials may be subject to Third Party proprietary rights (e.g., copyrights) and Genentech’s use thereof is subject to such rights. At the time FMI provides to Genentech any FMI Provided Materials that include content subject to
the proprietary rights of a Third Party, FMI shall identify in writing such Third Party content and the identity of such Third Party. 
  

	 	6.1.2	License Grant to Genentech; Educational Materials 

 FMI hereby grants to Genentech and its Affiliates a non-exclusive, perpetual, fully paid-up, irrevocable, non-sublicensable, worldwide license to incorporate FMI Provided Materials in the Educational Materials and similar
materials and to otherwise use the FMI Provided Materials in the Educational Activities and similar activities, including the right to create, reproduce and distribute the Educational Materials and similar materials and to authorize others to
do so on its behalf, in each case, subject to copyrights or similar rights of Third Parties; provided however, such license shall not include any right or license under FMI’s intellectual property rights to FMI’s corporate or product trade
names or trademarks. As between the Parties, Genentech shall solely own all right, title and interest in and to the Educational Materials and similar materials (excluding FMI Provided Materials and FMI Other Materials), and Genentech may, and may
have any authorized designee acting on behalf of Genentech, use the Educational Materials and similar materials for Genentech’s own purposes, including outside the scope of this Agreement. 

  
 ***Confidential Treatment
Requested*** 
 - 16 - 

	 	6.1.3	License Grant to FMI; FMI Other Materials 

 Genentech hereby grants to FMI and its Affiliates a non-exclusive, perpetual, fully paid-up, irrevocable, non-sublicensable, worldwide license to incorporate Genentech originated content
included in the Educational Materials in materials to be used by FMI for its own purposes (“FMI Other Materials”), including the right to create, reproduce and distribute FMI Other Materials including such content and to authorize
others to do so on its behalf, in each case, subject to copyrights or similar rights of Third Parties; provided, however such license shall not include any right or license under Genentech’s intellectual property rights to Genentech’s
corporate or product trade names or trademarks. FMI shall use trade dress (fonts, color scheme, design attributes) in connection with the FMI Other Materials sufficiently different from the trade dress of the Educational Materials so as not to
create any confusion, or mislead a reasonable person, as to whether Genentech is the owner or source of the FMI Other Materials. Prior to the initial instance of reproduction or distribution of FMI Other Materials to Third Parties, FMI shall provide
copies of such FMI Other Materials to Genentech. For the avoidance of doubt, certain Educational Materials may be subject to Third Party proprietary rights (e.g., copyrights) and FMI’s use thereof is subject to such rights. At the time
Genentech provides to FMI any Educational Materials that include content subject to the proprietary rights of a Third Party (other than such content that was provided by FMI to Genentech), Genentech shall identify in writing such Third Party content
and the identity of such Third Party. 
  

	6.2	No Implied Licenses 

 Except as specifically set forth herein, this Agreement shall not be construed as
(a) giving a Party any license, right, title, interest in or ownership to the Confidential Information or other proprietary information or materials of the other Party; (b) granting to a Party any license or right under any intellectual
property rights of the other Party; or (c) representing any commitment by either Party to enter into any additional agreement, by implication or otherwise. 
  

	7.	Representations and Warranties 

  

	7.1	Mutual Representations and Warranties 

 FMI and Genentech each represent and warrant that it: 

(a) has all requisite power and authority to enter into and perform its obligations under this Agreement; 

(b) has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude its
personnel from complying with the provisions hereof; and 
 (c) will perform all activities under this Agreement (i) in a professional
manner, (ii) in conformance with the level or care and skill ordinarily exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law. 

  
 - 17 - 

	7.2	No Other Representations 

 EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT AND THE RELATED AGREEMENTS
BEING ENTERED INTO BY THE PARTIES AT THIS TIME, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OF PRODUCTS. 
  

	8.	Liability 

 IN NO EVENT SHALL EITHER FMI OR GENENTECH BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 
  

	9.	Term and Termination 

  

	9.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date, and unless terminated
sooner as provided in Article 9, continue for the Agreement Term. 
  

	9.2	Termination 

  

	 	9.2.1	Termination for Breach 

 A Party (“Non-Breaching
Party”) shall have the right to terminate this Agreement in its entirety in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach. The Breaching Party shall have a period of [...***...] after such written notice is provided
(“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a bona fide dispute as to whether such breach occurred or has been cured, it will so notify the
Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 11.2. Upon a determination of breach or failure to cure, the
Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching
Party’s request for termination, this Agreement shall terminate effective as of the expiration of the Peremptory Notice Period. 
  

	 	9.2.2	Termination for Regulatory, Compliance and Other Matters 

 A Party shall have the right to terminate this
Agreement on [...***...] notice and to immediately suspend any affected activities under the Agreement, if (a) it receives a communication from a Government Agency to the effect that one or more activities by either or both Parties under
the 

  
 ***Confidential Treatment
Requested*** 
 - 18 - 

 
Agreement violates Applicable Law including, without limitation, any Healthcare Law, and regulations promulgated under the foregoing laws; (b) a Government Agency promulgates a regulation
during the Agreement Term that is or would be violated by one or more activities by either or both Parties under the Agreement; (c) a Government Agency issues an opinion, guidance or interpretation during the Agreement Term that reasonably
indicates that it is the position of such Government Agency that activities of the nature of one or more activities by either or both Parties under the Agreement violates or would violate Applicable Law including, without limitation any Healthcare
Law, and regulations promulgated under any such laws; or (d) such Party has a right to terminate the Agreement under Section 2.2.3. 
  

	 	9.2.3	Termination for Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs
an Insolvency Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding
is not dismissed within [...***...] after the filing thereof. 
  

	 	9.2.4	Termination Without a Cause 

 Each Party shall have the right to terminate this Agreement in its entirety, in
its sole discretion, during the first Calendar Year of the Agreement upon six (6) months’ prior written notice to the other Party and thereafter upon three (3) months’ prior written notice to the other Party. 

 

	9.3	Consequences of Termination 

  

	 	9.3.1	Accrued Rights and Obligations 

 Except as otherwise expressly provided in this Agreement, termination of this
Agreement shall not affect the rights and obligations of the Parties that accrued prior to the effective date of such termination, including any obligation that FMI has to make payments to Genentech that are due and payable prior to the effective
date of termination. Any right that a Party has to terminate this Agreement, and any rights that such Party has under Article 9, shall be in addition to and not in lieu of all other rights or remedies that such Party may have at law or in
equity or otherwise, including rights under the Bankruptcy Code. 
  

	 	9.3.2	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by
FMI to Genentech are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (“Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101 of the Bankruptcy Code. 
  

	9.4	Survival 

 Article 6 (Intellectual Property), Article 7 (Representations and Warranties),
Article 8 (Liability), Article 9 (Term and Termination), Article 10 (Matters Governed by the Collaboration Agreement), and Article 11 (Miscellaneous) (to the extent applicable) shall survive any expiration or termination of this
Agreement for any reason. 

  
 ***Confidential Treatment
Requested*** 
 - 19 - 

	10.	Matters Governed by the Collaboration Agreement 

  

	10.1	Auditing 

 Except as otherwise specified herein, the auditing provisions of the Collaboration Agreement
shall apply any payments made by one Party to the other Party under this Agreement (e.g., with respect to payments by FMI to Genentech for FTE Costs) mutatis mutandis. 

 

	10.2	Indemnification 

 Except as otherwise specified herein, the indemnification provisions of the
Collaboration Agreement shall apply to this Agreement mutatis mutandis. 
  

	10.3	Confidentiality 

 Except as otherwise specified herein, the confidentiality provisions of the
Collaboration Agreement shall apply to any Confidential Information obtained by a Party or its Affiliates under this Agreement mutatis mutandis. 
  

	10.4	Assignment 

 Except as otherwise specified herein, the assignment provisions of the Collaboration
Agreement shall apply to this Agreement mutatis mutandis. 
  

	10.5	Debarment and Exclusion 

 Except as otherwise specified herein, the Parties’ representations,
warranties and covenants with respect to debarment and exclusion in the Collaboration Agreement shall apply to this Agreement mutatis mutandis. 
  

	11.	Miscellaneous 

  

	11.1	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
York, US, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

 

	11.2	Disputes 

 Unless otherwise set forth in this Agreement (e.g., Section 2.2.3), in the event of
any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated
executive officers are as follows: 
 For FMI: CEO 

For Genentech: Head of Roche Partnering 

  
 - 20 - 

 Should the Parties fail to agree within the time period set forth in the Collaboration Agreement for dispute
resolution by the Parties, except as otherwise specified herein, the arbitration provisions of the Collaboration Agreement shall apply to disputes arising under this Agreement mutatis mutandis. 

 

	11.3	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and
notwithstanding any other provision of this Agreement to the contrary, FMI legal relationship to Genentech under this Agreement shall be that of independent contractor. 
  

	11.4	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e., the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	11.5	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	11.6	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

 

	11.7	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 
  

	11.8	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	11.9	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by
Genentech to FMI by email at the following address or other address as FMI may later provide: 
 Foundation Medicine, Inc. 

ap@foundationmedicine.com 

  
 - 21 - 

	11.10	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to FMI, to:		 Foundation Medicine, Inc.
 150 Second Street

Cambridge, Massachusetts 02141
 Attn: Legal Department

Facsimile No.: +1 617-418-2201

		
	if to Genentech, to:		 Genentech, Inc.
 1 DNA Way

Attn: Corporate Secretary
 Facsimile No.: +1
650-467-9146

		
	and:		 Genentech, Inc.
 1 DNA Way

Attn: Global Head, Alliance and Asset Management
 Facsimile No.:
+1 650-467-3294

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 22 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Steven J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

			
	Genentech, Inc.
	
	 /s/ Ian T. Clark

		
	Name:		Ian T. Clark
		
	Title:		Chief Executive Officer

  
 - 23 - 

 Appendix 2.1.5 

Tactical Plan 
 US
Education Collaboration Agreement 
 2015 Tactical Plan 

Capitalized terms used in this Tactical Plan shall have the meaning given them in the US Education Collaboration Agreement unless otherwise defined
herein. 
 Term: Effective Date to [...***...] 
 A.
Training Activities 
 [...***...]. 
 B.
Development of Educational Materials 
 [...***...]. 

C. PREP Educational Activities 
 [...***...]. 

D. Educational Speaker Programs 
 [...***...]. 

E. Information Sharing 
 [...***...]. 

F. Costs and Compensation 
 [...***...]. 

G. [...***...] Tactical Plan 
 The Parties,
through the ESWG, will consider whether to incorporate a CGP education effectiveness metric to be tracked and assessed for the [...***...] tactical plans and/or subsequent tactical plans as they develop more insight and experience with this
collaboration. 

  
 ***Confidential Treatment
Requested*** 
 A-1EX-10.5

 Exhibit 10.5 

EXECUTION COPY 
 ***Text Omitted and Filed
Separately with the Securities and Exchange Commission 
 Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Foundation Medicine/Roche 

Binding Term Sheet for an In Vitro Diagnostics Collaboration 

This summary of terms (this “Binding Term Sheet”) between Foundation Medicine, Inc. (“FMI”) and F. Hoffmann-La Roche Ltd
(“Roche”) (each a “Party,” and collectively the “Parties”), sets forth certain terms and conditions relating to an in vitro diagnostics (“IVD”) collaboration between the Parties
(“IVD Collaboration”), which will include transactions regarding the worldwide development and commercialization of IVD versions of FMI’s products and services. 

It is expressly agreed that this Binding Term Sheet shall be binding upon the Parties as of the Effective Date and shall only be superseded if the Parties
execute a more definitive agreement (“Definitive Agreement”) reflecting additional detail with respect to the terms and conditions set forth herein, as well as any other terms and conditions as the Parties may mutually agree. The
completion and execution of the Definitive Agreement shall be subject to the approval of the management and/or Boards of Directors of both Parties, as applicable. 

Capitalized terms used herein shall have the meanings provided above or as defined below. 

 

			
	Affiliates		The Parties recognize that Roche operates as a network of affiliated companies. Accordingly, the Definitive Agreement may be entered into by one or more Roche affiliates and Roche’s rights and obligations under the Definitive
Agreement may be performed by or extended to multiple Roche affiliates. Roche shall ensure that each such Roche affiliate complies with the terms and conditions of the Definitive Agreement. For the avoidance of doubt, Roche and FMI are not an
affiliate of one another for purposes of this Binding Term Sheet.
		
	Confidentiality		The terms and conditions of this Binding Term Sheet, as well as any Information (as defined in the confidentiality agreement entered into by a Roche affiliate and FMI on June 9, 2014 (the “Existing CDA”)) disclosed
by one Party to the other Party in connection with the transactions contemplated by this Binding Term Sheet and negotiations related thereto are subject to the Existing CDA.
		
	Binding Term Sheet Term and Termination		This Binding Term Sheet shall commence on the Effective Date and remain in full force and effect until terminated by mutual written agreement duly executed by the Parties (the “Binding Term Sheet

  

			
			Term”). The terms and conditions set forth in the sections entitled “Confidentiality”, “Roche MFN” and “Miscellaneous” shall survive any termination of this Binding Term Sheet. For purposes
of this Binding Term Sheet, “Effective Date” shall have the meaning set forth in the Collaboration Agreement.
		
	Efforts to Negotiate and Enter into Agreement		 The Parties will use commercially reasonable efforts to (i) negotiate, in good faith, the terms of the Definitive Agreement, which shall
reflect additional detail with respect to the terms and conditions set forth in this Binding Term Sheet, as well as any other terms and conditions as the Parties may mutually agree, and (ii) enter into such Definitive Agreement as soon as
practicable after the Effective Date, but no later than one (1) year after the closing of a series of transactions between the Parties and/or their respective affiliates entered contemporaneously on the Effective Date (which period may be extended
by mutual written agreement of the Parties).
  
 In addition to the foregoing, FMI shall
[...***...] if Roche so requests, enter into the Definitive Agreement with Roche no later than [...***...] thereafter on the terms set forth herein, including any terms required by the terms and conditions set forth in the section
entitled “Roche MFN”. If FMI and Roche are unable to agree to any additional terms of such Definitive Agreement within such [...***...] period, then the Parties shall refer such dispute to the JMC (as defined below), which shall have
[...***...] to resolve such dispute by consensus. If there are any matters not resolved by the JMC within such [...***...] period, then the Parties shall each select and agree upon a mutually acceptable independent third party expert who
is neutral, disinterested and impartial, and has significant relevant experience in the development and commercialization of diagnostic products (each, an “Expert”). Each Expert shall within [...***...] select a third
Expert to form a panel of three (3) Experts (“Panel”). The date on which such Panel is selected will be the “Arbitration Commencement Date.” Each Party shall within [...***...] following the Arbitration
Commencement Date prepare and deliver to both the Panel and the other Party its proposed terms that have not been agreed (collectively, the “Arbitration Offer”) to resolve the disputed matter and a memorandum (the
“Supporting Memorandum”) in support thereof; provided that such Arbitration Offer shall be on the same or substantially similar terms as the last offer made by such Party to the other Party during the initial [...***...]
period. The Panel will also be provided with a copy of this Binding Term Sheet and any agreements that are relevant to interpretation of the terms and conditions set forth in the section entitled “Roche
MFN”. Within

  
 ***Confidential Treatment
Requested*** 

			
		  	[...***...] after receipt of the other Party’s Supporting Memorandum, each Party may submit to the Panel (with a copy to the other Party) a rebuttal to the other Party’s Supporting Memorandum (a
“Rebuttal”), which may include a revision, marked to show changes, of either Party’s proposed terms. Neither Party may have communications (either written or oral) with the Panel other than for the sole purpose of engaging
the Panel or as expressly permitted in this section. Within [...***...] after the Panel’s receipt of each Party’s Rebuttal (or the expiration of the period for the Parties to submit a Rebuttal, if earlier), the Panel will select,
between the proposals provided by the Parties, the proposal that the Panel believes most accurately reflects an equitable result for FMI and Roche based on the requirements of this Binding Term Sheet (the “Selected Terms”). The
Panel shall not have the authority to modify a proposal initially submitted by a Party. The decision of the Panel shall be the sole, exclusive and binding remedy and the Selected Terms shall automatically become incorporated into the Definitive
Agreement and such Definitive Agreement shall automatically become a binding and enforceable agreement between the Parties. The Panel will have reasonable discretion to request additional information, hold a hearing, and extend the time frame for
reaching a decision regarding the dispute at issue. The Panel’s fees and expenses will be paid by the Party whose proposal is not selected by the Panel. Each Party will bear and pay its own expenses incurred in connection with any
proceedings under this section.
		
	Diligence	  	The Parties will exercise commercially reasonable efforts in performing their obligations under the IVD Collaboration, including in connection with the evaluation of proposals to develop and commercialize IVD Kit Products (as
defined below).
		
	Governance; Dispute Resolution	  	The responsibilities of the Joint Research and Development Committee (“JRDC”) and Joint Management Committee (“JMC”) established by the Collaboration Agreement (as defined below) shall be extended
to apply to the IVD Collaboration. In furtherance of the foregoing, the provisions of Article 6 of the Collaboration Agreement are incorporated herein and shall apply mutatis mutandis; provided that Sections 6.1.2, 6.1.5.1, 6.1.5.2, 6.1.7,
6.3, and 6.7 shall not apply to this Binding Term Sheet or any activities under the IVD Collaboration. For the avoidance of doubt, (i) the JRDC’s responsibilities shall include evaluating in good faith proposals to develop and commercialize IVD
Kit Products and overseeing the IVD Development Working Group (as defined below), (ii) each of the JRDC and JMC will make decisions related to the IVD Collaboration by consensus of the Parties, (iii) unresolved issues at
the

  
 ***Confidential Treatment
Requested*** 

			
		  	 JRDC will be addressed by the JMC, (iv) unresolved issues at the JMC will be addressed by the CEOs of Roche and FMI (or their designees), and
(v) issues not resolved by the CEOs shall be resolved by [...***...]. For clarity, for purposes of the foregoing governance and dispute resolution terms and conditions, but subject to the terms and conditions set forth in the section entitled
“Roche MFN” below, (a) neither Party may unilaterally exercise deciding authority to compel the other Party to pursue development and commercialization of any IVD Kit Product (including any Roche IVD Kit Product), and (b) any such
development and commercialization of any such IVD Kit Product (or Roche IVD Kit Product) under the IVD Collaboration shall require mutual agreement of the Parties.
  

For the purposes of this Binding Term Sheet, “Collaboration Agreement” means that certain Collaboration Agreement entered into between the
Parties concurrently with this Binding Term Sheet relating to the use of FMI’s molecular information platform and the development of immunotherapy, circulating tumor DNA and companion diagnostics platforms.

		
	Working Group	  	 The JRDC shall establish a working group (the “IVD Development Working Group”) to oversee the activities contemplated under
each IVD Agreement.
  
 The IVD Development Working Group will make recommendations to the
JRDC regarding planned IVD Collaboration activities between Roche and FMI and related budgets. Further authorities might be granted to the IVD Development Working Group by the JRDC.

		
	Definitive Agreement/IVD Agreement Term and Termination	  	The term of the Definitive Agreement (“Definitive Agreement Term”) shall be a period commencing on the effective date of the Definitive Agreement and, unless earlier terminated by the Parties in accordance with the
terms of the Definitive Agreement, expiring five (5) years from such effective date, unless extended by Roche for additional two (2) year periods of time during any period of time in which the Aggregate Ownership Percentage (as defined in the
Investor Rights Agreement) of Roche and its affiliates is at least fifty percent (50.1%) (it being understood that this requirement is subject to Section 4.04 of the Investor Rights Agreement). For purposes of this Binding Term Sheet, the Definitive
Agreement and each IVD Agreement, (i) “Transaction Agreement” means that certain Transaction Agreement entered into between Roche and FMI concurrently with the execution of this Binding Term Sheet (as amended from time to time) and
(ii) “Investor Rights Agreement” shall have the meaning set forth in the Transaction Agreement.

  
 ***Confidential Treatment
Requested*** 

			
			 Notwithstanding the Definitive Agreement Term, if the Parties execute an agreement specifically governing the development, manufacture, use
and commercialization of any IVD Kit Product (defined below) (each such agreement, an “IVD Agreement”), the initial term of each such IVD Agreement with respect to such IVD Kit Product shall be five (5) years (the “Initial
IVD Agreement Term”) from the date of execution thereof. Such Initial IVD Agreement Term may be extended by Roche, at its option, for one additional three (3) year period during any period of time in which the Aggregate Ownership Percentage
(as defined in the Investor Rights Agreement) of Roche and its affiliates is at least fifty percent (50.1%) (it being understood that this requirement is subject to Section 4.04 of the Investor Rights Agreement)(the Initial IVD Agreement Term and
any such extension are together referred to as the “IVD Agreement Term”). For clarity, the IVD Agreement Term shall be determined on an IVD Kit Product-by-IVD Kit Product basis.

 
 For the avoidance of doubt, notwithstanding anything in this Binding Term Sheet to the
contrary, if any IVD Kit Product is developed under any IVD Agreement during the applicable IVD Agreement Term, the right of Roche to manufacture, distribute and sell such IVD Kit Product shall continue for as long as such IVD Kit Product is
commercialized by or on behalf of Roche or any of its affiliates, subject to applicable ongoing terms established in such IVD Agreement, including the payment of any royalties, milestones and similar payments.

 
 Termination provisions of the Definitive Agreement, including consequences of termination,
will be set forth in the Definitive Agreement.

		
	Overview		By entering into the IVD Collaboration, Roche and FMI intend for this Binding Term Sheet and the Definitive Agreement to establish a framework for potential future collaboration(s) to manufacture, distribute and commercialize IVD
versions of FMI’s products, services and tests (“IVD Kit Products”). FMI’s products shall mean (i) FMI’s existing products and services (including, but not limited to, FoundationOne® and FoundationOne® Heme) and any and all successor products and services, (ii) any and all products and services developed under the
Collaboration Agreement and (iii) any and all other future products or services developed by FMI.

  

			
			 The Parties will work non-exclusively with each other in the development of IVD Kit Products, provided, however, FMI shall work exclusively
with Roche with regard to Roche IVD Kit Products (as defined below). For clarity, subject to the terms and conditions of this Binding Term Sheet (including the terms and conditions set forth in the section entitled “Roche MFN”), both
Parties are free to explore and execute kit development and commercialization internally or with third parties on other platforms, provided, however, FMI shall not develop internally or with a third party IVD Kit Products for or using any Roche
Platform (as defined below) without the prior written consent of Roche.
  
 In furtherance
of the foregoing, the rights granted by FMI to Roche under the this Binding Term Sheet, the Definitive Agreement and each IVD Agreement shall be (A) exclusive with respect to (1) Roche IVD Kit Products, (2) Roche Platforms and (3) any IVD Kit
Products within any Roche Exclusive Field (collectively, “Roche Exclusive Products”) and (B) otherwise non-exclusive. For the avoidance of doubt, FMI and its affiliates shall work exclusively with Roche in the development and
commercialization of Roche Exclusive Products, and neither FMI nor any of its affiliates shall compete with Roche or any of its affiliates with respect to any Roche Exclusive Field. FMI shall not, and shall cause its affiliates not to, grant any
third party any rights with respect to any IVD Kit Product that conflict with or otherwise limit any of the rights granted (or contemplated to be granted) to Roche and its affiliates under this Binding Term Sheet, the Definitive Agreement or any IVD
Agreement.
  
 For the purposes of this Binding Term Sheet, the Definitive Agreement and
each IVD Agreement, (x) “Roche IVD Kit Product” means any IVD Kit Product that utilizes a Roche Platform, (y) “Roche Platform” means any sequencing platform owned or controlled by Roche or any of its affiliates, and
(z) “Roche Exclusive Field” means any designated IVD Kit Product field (including disease indication) as the Parties may mutually agree.
  

Subject to the terms and conditions of this Binding Term Sheet (including the terms and conditions set forth in the section entitled “Roche MFN” and,
with respect to FMI, the terms and conditions set forth in the section entitled “Efforts to Negotiate and Enter into Agreement” with respect to the occurrence of a “Trigger Event”),
[...***...].

  
 ***Confidential Treatment
Requested*** 

			
	Development of IVD Kit Products, Selection of Sequencing Platform		 This Binding Term Sheet and the Definitive Agreement - as a framework agreement - will enable one or more IVD Agreements governing IVD Kit
Product development and commercialization to be agreed between the Parties and will govern matters on an IVD Kit Product-by-IVD Kit Product basis.
  

Any IVD Agreement will contain provisions that:
  

•   The Parties, through the IVD Development Working Group, will discuss and align on overall
strategy, development, and marketing plans for Roche Exclusive Products;
  

•   Roche will develop Roche Exclusive Products and be the legal manufacturer of such Roche
Exclusive Products;
  

•   Specify [...***...] under any such IVD Agreement.

 
 •   Roche [...***...]
of development for Roche Exclusive Products;
  

•   Roche will be granted exclusive, sublicensable and assignable rights (including intellectual
property rights) to manufacture, use, distribute, sell, offer for sale, import and otherwise commercialize Roche Exclusive Products in the United States and/or outside of the United States;

 
 •   FMI will provide
analytical, interpretation, and reporting services for samples processed using Roche Exclusive Products or alternatively will enable Roche to use, directly and on a non-sublicensable basis, FMI’s database for analysis, interpretation, and
reporting purposes, and Roche [...***...] related to such Roche Exclusive Products, if any;
  

•   FMI will be entitled [...***...] of Roche Exclusive Products;

 
 •   FMI will be entitled
[...***...] related to Roche Exclusive Products, [...***...] of the development of such Roche Exclusive Products;
  

•   [...***...], and 

 
 •   Governance provisions
will be as set forth above.
  
 Each IVD Agreement shall define additional terms,
including a work plan and budget.

  
 ***Confidential Treatment
Requested*** 

			
	Additional FMI Responsibilities		 Research and Platform Development:
  

FMI will provide genomic analysis, interpretation expertise, and application support in connection with the development of the Roche Platform for use in
clinical cancer profiling, on terms to be mutually agreed by the Parties (such activities are hereinafter “FMI Development Obligations”).

		
	Financial Terms		 Roche Platform Development:
  

Roche shall control the development of the Roche Platform, [...***...] of any FMI Development Obligations.

		
	Roche MFN		 FMI acknowledges and agrees that the rights granted and contemplated to be granted to Roche and its affiliates with respect to IVD Kit
Products under this Binding Term Sheet, the Definitive Agreement and each IVD Agreement are and shall be, when considered as part of an integrated whole, no less favorable to Roche and its affiliates than any terms and conditions granted by FMI or
any of its affiliates to any third party with respect to the development, commercialization or other exploitation of any IVD Kit Product.
  

If, at any time after the Effective Date, FMI or any of its affiliates enters into any agreement (“Third Party Agreement”) with any third
party pursuant to which FMI or any of its affiliates grants such third party any right to develop, commercialize or otherwise exploit any IVD Kit Product and such agreement includes any terms or conditions that are more favorable, when taken as a
whole, than those provided to Roche and its affiliates under this Binding Term Sheet, the Definitive Agreement or any IVD Agreement (“More Favorable Provisions”), then FMI shall promptly provide written notice thereof to Roche, and
Roche may elect, at its discretion, to receive the benefit of such More Favorable Provisions under the Definitive Agreement and each IVD Agreement, whether then in effect or entered into thereafter (it being understood that, if no Definitive
Agreement has been entered into between the Parties at the time such More Favorable Provisions have been provided to any such third party, a Trigger Event shall be deemed to have occurred). Upon any such election by Roche, the Definitive Agreement
and each IVD Agreement, as applicable, shall automatically be deemed to have been amended and modified such that, from the date on which any such More Favorable Provisions are first so provided to a third party and thereafter, Roche and its
affiliates shall be provided such More

  
 ***Confidential Treatment
Requested*** 

			
			 Favorable Provisions (it being understood that, if Roche elects to accept such More Favorable Provisions with respect to any Definitive
Agreement or IVD Agreement in which the Relevant Terms thereof are materially different than the Relevant Terms of the Third Party Agreement, the Parties shall, in good faith, use commercially reasonable efforts to modify such More Favorable
Provisions in a manner that accounts for such difference).
  
 For the purposes of this
Binding Term Sheet, the Definitive Agreement and each IVD Agreement, “Relevant Terms” means, with respect to any agreement for the development, commercialization or other exploitation of IVD Kit Products, the (i) scope of work to be
pursued thereunder, including the type and number of IVD Kit Products to be developed, (ii) geographic scope of such development, commercialization or other exploitation, (iii) [...***...] and (iv) [...***...].

 
 Notwithstanding anything in this Binding Term Sheet, the Definitive Agreement or any IVD
Agreement to the contrary, neither FMI nor any of its affiliates shall take any action designed or intended to evade, frustrate or otherwise circumvent the intent or purpose of this section.

		
	Miscellaneous		This Binding Term Sheet shall be governed by the laws of the State of New York, without regard to the conflicts of law rules of such state. The Parties acknowledge and agree that the United Nations Convention on Contracts for the
International Sale of Goods (the Vienna Convention) shall not apply to this Binding Term Sheet. The provisions of Sections 19.2 and 19.3 of the Collaboration Agreement are incorporated herein and shall apply mutatis mutandis. Neither Party
shall have the right to assign or otherwise transfer this Binding Term Sheet or any part thereof to any third party without the prior written approval of the other Party, provided that either Party may assign this Binding Term Sheet to any of its
affiliates without the approval of the other Party. If any of the provisions of this Binding Term Sheet are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will
achieve as far as possible the economic business intentions of the Parties; provided, however, that the remainder of this Binding Term Sheet will remain in full force and effect to the extent that the material interests of
the

  
 ***Confidential Treatment
Requested*** 

			
			Parties are not affected. Any provision of this Binding Term Sheet may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each Party, or in the case of a
waiver, by the Party against whom the waiver is to be effective. The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Binding Term Sheet will neither constitute a
waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. This Binding Term Sheet, the Collaboration Agreement and the Existing CDA contain the entire understanding between the Parties with
respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the Parties with respect to the subject matter hereof and thereof. This Binding Term Sheet may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

 [Signature Page Follows] 

  

 IN WITNESS WHEREOF, the Parties have entered into this Binding Term Sheet as of the Effective Date. 

 

			
	Foundation Medicine, Inc.
	
	 /s/ Steven J. Kafka

		
	Name:		Steven J. Kafka
		
	Title:		Chief Operating Officer

  

									
	F. Hoffmann-La Roche Ltd						
			
	 /s/ Christian Hebich
				 /s/ Roland Diggelmann

					
	Name:		Christian Hebich				Name:		Roland Diggelmann
					
	Title:		Head of Finance/Services Roche Diagnostics				Title:		COO Roche Diagnostics

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]